Maternal “mirror” syndrome: Evaluating the benefits of fetal therapy
Prenatal Diagnosis · 2024
DOI: 10.1002/pd.6589 ↗At a glance
Multizentrische Studie in Prenatal Diagnosis, 2024. Written by Joanna Sichitiu and 12 co-authors. Institution: Fetal Medicine Unit, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. Major MEDLINE topics: Hydrops Fetalis, Fetal Therapies. Cited 14 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Objective
To evaluate maternal and perinatal outcomes following fetal intervention in the context of maternal “mirror” syndrome. Study Design A multicenter retrospective study of all cases of fetal hydrops complicated by maternal “mirror” syndrome and treated by any form of fetal therapy between 1995 and 2022. Medical records and ultrasound images of all cases were reviewed. “Mirror” syndrome was defined as fetal hydrops and/or placentomegaly associated with the maternal development of pronounced edema, with or without pre‐eclampsia. Fetal hydrops was defined as the presence of abnormal fluid collections in ≥2 body cavities.
Results
Twenty‐one pregnancies met the inclusion criteria. Causes of fetal hydrops and/or placentomegaly included fetal lung lesions ( n = 9), twin‐twin transfusion syndrome ( n = 6), severe fetal anemia ( n = 4), and others ( n = 2). Mean gestational age at “mirror” presentation was 27.0 ± 3.8 weeks. Maternal “mirror” syndrome was identified following fetal therapeutic intervention in 14 cases (66.6%). “Mirror” symptoms resolved or significantly improved before delivery in 8 (38.1%) cases with a mean interval from fetal intervention to maternal recovery of 13.1 days (range 4–35). Three women needed to be delivered because of worsening “mirror” syndrome. Of the 21 pregnancies treated (27 fetuses), there were 15 (55.5%) livebirths, 7 (25.9%) neonatal deaths and 5 (18.5%) intra‐uterine deaths.
Conclusion
Following successful treatment and resolution of fetal hydrops, maternal “mirror” syndrome can improve or sometimes completely resolve before delivery. Furthermore, the recognition that “mirror” syndrome may arise only after fetal intervention necessitates hightened patient maternal surveillance in cases of fetal hydrops.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Fetal Medicine Unit, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
- Ontario Fetal Centre, Toronto, Ontario, Canada.
- Woman-Mother-Child Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
- Division of Neonatology, Department of Paediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
- Department of Obstetrics & Gynecology, University Hospitals Leuven, Leuven, Belgium.
ORCID profiles: Joanna Sichitiu, Rory Windrim, Liesbeth Lewi, Jan Deprest
Cite
APA
Sichitiu, J., Alkazaleh, F., de Heus, R., Abbasi, N., van Mieghem, T., Keunen, J., Windrim, R., Seaward, G., Kelly, E. N., Lewi, L., Deprest, J., Ryan, G., & Shinar, S. (2024). Maternal “mirror” syndrome: Evaluating the benefits of fetal therapy. Prenatal Diagnosis. https://doi.org/10.1002/pd.6589
Vancouver
Sichitiu J, Alkazaleh F, de Heus R, Abbasi N, van Mieghem T, Keunen J, et al. Maternal “mirror” syndrome: Evaluating the benefits of fetal therapy. Prenatal Diagnosis. 2024. doi:10.1002/pd.6589
BibTeX
@article{Sichitiu2024,
author = {Sichitiu, Joanna and Alkazaleh, Fawaz and de Heus, Roel and Abbasi, Nimrah and van Mieghem, Tim and Keunen, Johannes and Windrim, Rory and Seaward, Gareth and Kelly, Edmond N and Lewi, Liesbeth and Deprest, Jan and Ryan, Greg and Shinar, Shiri},
title = {Maternal “mirror” syndrome: Evaluating the benefits of fetal therapy},
journal = {Prenatal Diagnosis},
year = {2024},
doi = {10.1002/pd.6589}
}
EUVIMED